primaquine has been researched along with Chylopericardium in 1 studies
Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)
primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaagaard, MD | 1 |
| Matos, LO | 1 |
| Holm, AE | 1 |
| Gomes, LC | 1 |
| Wegener, A | 1 |
| Lima, KO | 1 |
| Vieira, IVM | 1 |
| de Souza, RM | 1 |
| Marinho, CRF | 1 |
| Hviid, L | 1 |
| Vestergaard, LS | 1 |
| Dominguez, H | 1 |
| Biering-Sørensen, T | 1 |
| Silvestre, OM | 1 |
| Brainin, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Malaria Heart Disease Study: A Novel Pathway to Subclinical Heart Disease[NCT04445103] | 597 participants (Actual) | Observational | 2020-06-21 | Terminated (stopped due to Due to the COVID-19 pandemic it was not possible to complete the study inclusion as originally anticipated.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for primaquine and Chylopericardium
| Article | Year |
|---|---|
Frequency of Electrocardiographic Alterations and Pericardial Effusion in Patients With Uncomplicated Malaria.
Topics: Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Brazil; Case-Control Studies; Chlor | 2022 |